Business Description
ISIN : US05350V1061
Total Employee Number:
2,287Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.47 | |||||
Equity-to-Asset | 0.75 | |||||
Debt-to-Equity | 0.18 | |||||
Debt-to-EBITDA | -6.41 | |||||
Interest Coverage | 1.94 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 2.3 | |||||
Beneish M-Score | -2.59 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 1.5 | |||||
3-Year EPS without NRI Growth Rate | -17.1 | |||||
3-Year FCF Growth Rate | -15 | |||||
3-Year Book Growth Rate | -15.5 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 69.6 | |||||
9-Day RSI | 60.57 | |||||
14-Day RSI | 62.1 | |||||
3-1 Month Momentum % | 1.18 | |||||
6-1 Month Momentum % | 90.6 | |||||
12-1 Month Momentum % | 110.02 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.48 | |||||
Quick Ratio | 1.4 | |||||
Cash Ratio | 0.5 | |||||
Days Inventory | 147.12 | |||||
Days Sales Outstanding | 54.29 | |||||
Days Payable | 52.42 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 0.1 | |||||
Shareholder Yield % | 4.33 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 50.05 | |||||
Operating Margin % | 1.96 | |||||
Net Margin % | -10.39 | |||||
EBITDA Margin % | -3.02 | |||||
FCF Margin % | 1.05 | |||||
OCF Margin % | 5.13 | |||||
ROE % | -9.41 | |||||
ROA % | -6.97 | |||||
ROIC % | 1.63 | |||||
3-Year ROIIC % | 2.01 | |||||
ROC (Joel Greenblatt) % | -21.33 | |||||
ROCE % | -6.61 | |||||
Years of Profitability over Past 10-Year | 5 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 24.97 | |||||
PE Ratio without NRI | 27.77 | |||||
PS Ratio | 1.63 | |||||
PB Ratio | 1.49 | |||||
Price-to-Tangible-Book | 4.27 | |||||
Price-to-Free-Cash-Flow | 146.14 | |||||
Price-to-Operating-Cash-Flow | 31.28 | |||||
EV-to-EBIT | -20.35 | |||||
EV-to-EBITDA | -57.57 | |||||
EV-to-Revenue | 1.74 | |||||
EV-to-FCF | 165.8 | |||||
Price-to-GF-Value | 1.29 | |||||
Price-to-Projected-FCF | 1.2 | |||||
Price-to-Median-PS-Value | 0.73 | |||||
Price-to-Graham-Number | 2.3 | |||||
| Price-to-Net-Current-Asset-Value | 20.48 | |||||
Earnings Yield (Greenblatt) % | -4.91 | |||||
FCF Yield % | 0.64 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NYSE:AVNS
Peter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Avanos Medical Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 715.9 | ||
| EPS (TTM) ($) | -1.61 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | 0.15 | ||
| 3-Year Sortino Ratio | 0.33 | ||
| Volatility % | 78.13 | ||
| 14-Day RSI | 62.1 | ||
| 14-Day ATR ($) | 0.064901 | ||
| 20-Day SMA ($) | 24.9315 | ||
| 12-1 Month Momentum % | 110.02 | ||
| 52-Week Range ($) | 9.303 - 25.49 | ||
| Shares Outstanding (Mil) | 46.85 |
Piotroski F-Score Details
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Avanos Medical Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Avanos Medical Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-24 09:00 | In 181 days | ||
| Annual report for 2026 | 2027-02-24 | In 180 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-24 | In 180 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-05 09:00 | In 70 days | ||
| Third quarter earnings results for 2026 | 2026-11-05 | In 69 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-05 09:00 | 24.98 (-0.04%) | ||
| Second quarter earnings results for 2026 | 2026-08-05 | 24.98 (-0.04%) | ||
| First quarter earnings conference call for 2026 | 2026-05-12 | 24.81 (+0.12%) | ||
| First quarter earnings results for 2026 | 2026-05-05 | 24.66 (-0.08%) | ||
| General meeting for 2026 | 2026-04-21 09:00 | 24.64 (+0.08%) |
Avanos Medical Inc Frequently Asked Questions
Guru Commentaries on NYSE:AVNS
Avanos Medical Inc was acquired for a 72% premium, highlighting its value as a leading provider of feeding tubes to hospitals and medical facilities, operating with ~20% margins. The company was previously obscured by consolidated financials due to its less profitable pain management segment. However, a new CEO has made it clear that he intends to surface this value, which he successfully did through the acquisition. This demonstrates the underlying strength and potential of Avanos as a solid investment.
Avanos Medical has a strong market position in the enteral feeding segment, which features mid-single-digit revenue growth and a double-digit operating margin. The company has faced challenges in its hospital pain segment, but the recent leadership change and acquisition agreement with American Industrial Partners for $25 per share, representing a 72% premium, highlight its potential. The stock was trading at an all-time low, creating an ideal setup for value-focused investors. Our cost basis of $12.15 represents a gain of 106% at the takeout price, and we expect M&A to continue contributing to the Fund's returns.
Press Release
Articles on Avanos Medical Inc
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
